Home » Programs > Functional Glycobiology > Translation

Translation

Since its inception in 2005, the group has assembled a dossier of publications, analytical, physiological, clinical, and molecular methods and protocols, patents on structure-function relationships of a number of oligosaccharide compounds, microbial genetic sequences, and structural databases related to bioactive components found in human milk, which are currently being translated to commercially viable sources of oligosaccharides from bovine milk and other sources. The first generation of products will include a range of prebiotic compounds for the deflection of pathogens, including anti-viral and anti-microbial activity, the modulation of intestinal signaling and whole-body metabolism, as well as inflammation.

Patents

The Functional Glycobiology Program has developed a patent portfolio focusing on the functional attributes of health-promoting bioactive ingredients and technologies for bringing them to market. The first generation of patents has focused on the interaction between beneficial gut bacteria and their human hosts.

Please follow the link below to the UC Davis Office of Technology Transfer Innovation Access website where you will find a list of technologies that may be available for licensing, their description, a link to the published patent applications, as well as contact information if you would like more information or if you are interested in licensing the technology:

  1. 2007-242: HUMAN MILK OLIGOSACCHARIDES ENABLE GROWTH OF SELECT
  2. BENEFICIAL GUT BACTERIA
  3. US application published April 2009: Publication No. 20090098240
  4. http://techtransfer.universityofcalifornia.edu/NCD/11224.html
  5. 2007-152 (not available for licensing): BIFIDOBACTERIAL GENE SEQUENCES REQUIRED FOR CATABOLISM OF MILK OLIGOSACCHARIDES
  6. PCT application published 03/20/2008

Any other inquiries on technologies developed by the Functional Glycobiology Program and its patent portfolio should be addressed directly to Randi Jenkins at UC Davis Innovation Access.